Novo Nordisk, Sun Pharmaceutical endocrine/metabolic news
In a 2-1 decision, the U.S. Court of Appeals for the Federal Circuit upheld a lower court ruling that a claim in a Novo Nordisk patent related to the use of repaglinide plus metformin to treat Type II diabetes was invalid. Novo said the decision "favors approval and launch of a generic repaglinide product." In a 3-0 decision, the appeals court reversed the U.S. District Court for the District of Eastern Michigan decision that Novo Nordisk had committed inequitable conduct during the time the company attempted to acquire the patent. Novo said it will provide an update on the case along with its 1H13 earnings announcement in August. Novo recorded DKK1.2 billion ($212 million) in combined U.S. sales of Prandin repaglinide and PrandiMet repaglinide/metformin in 2012. Prandin is a short-acting beta cell stimulating meglitinides and PrandiMet is a combination of repaglinide and metformin. ...